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ABSTRACT 
 
Glidewell, Markie, Pharm.D., May 2017      Pharmacy 
 
University of Montana Students and the Gardasil® Vaccine 
 
Faculty Mentor: Donna Beall 
 
  Gardasil® is a vaccine for human papilloma virus (HPV), a sexually transmitted virus that can 
cause genital warts, cervical cancer, and other diseases. Males and females ages 9-26 are 
recommended to receive the Gardasil® vaccination. Most students attending the University of 
Montana (UM) are within the recommended age range for Gardasil® vaccination and would 
benefit from receiving it if they have not yet done so. Gardasil® is available at the Health 
Services Pharmacy on the UM campus and is often covered by insurance plans with no patient 
copay. In the fall semester of 2016, surveys were given to patients at the Health Services 
Pharmacy that inquired about the student’s Gardasil® vaccination status, barriers to vaccination 
they may encounter, their knowledge of HPV, and the student’s opinion of the Gardasil® 
vaccine. The results of the survey highlight a low vaccination rate in UM students, particularly in 
male students. Respondents were unaware of both the vaccine and its availability at the Health 
Services Pharmacy. In addition, a difference in knowledge about HPV was seen between 
vaccinated and unvaccinated individuals, with more vaccinated respondents correctly answering 
questions regarding Gardasil® and HPV. The results of this study suggest that a Gardasil® 
educational campaign should increase HPV awareness and vaccination rates in the student 
population at UM.  
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University of Montana Students and the Gardasil® Vaccine 
 
Introduction 
Gardasil® is a vaccination that protects against human papilloma virus (HPV), which can 
cause seven different types of cancers, in addition to genital warts and precancerous lesions. 
HPV is the most common sexually transmitted disease, with over 14 million new infections 
occurring each year in the US, half of which occur in people ages 15-24 years old.1 The majority 
of students that attend the University of Montana are within the recommended age range for 
Gardasil® vaccination. Gardasil® is available at the Health Service Pharmacy, a pharmacy 
located on the UM campus that is exclusively available to UM students. 
The purpose of this study is to assess the Gardasil® vaccination status of students at the 
University of Montana as well as their knowledge and opinion of the vaccine.  
 
Background 
The Gardasil® vaccine was introduced in the US in 2006. It provided protection against 
HPV types 6, 11, 16, and 18. HPV is transmitted through sexual contact and can cause genital 
warts, precancerous lesions, and cancers such as cervical, vulvar, vaginal, oropharyngeal, penile, 
anal, and rectal cancers.2 While some strains of HPV are mild and resolve spontaneously, 
approximately 13 strains are linked to the development of cancer.3 Gardasil 9®, which recently 
replaced Gardasil®, was approved in 2014 and provides coverage against five additional strains 
of HPV. Vaccination with Gardasil 9® is recommended for both males and females ages 9 
through age 26. Limitations of Gardasil® include the continued necessity of regular cervical and 
anal cancer screening, the inability to protect against HPV strains that a person has been exposed 
to prior to the vaccine, and the inability to treat active precancerous lesions and cancers.4 Even 
though the ideal time of vaccination is before the individual becomes sexually active, vaccination 
of sexually active individuals is still recommended because the individual may have not been 
exposed to every strain of HPV covered by the vaccine.  
A recent CDC analysis found that between 2008 and 2012, the rates of HPV-associated 
cancer incidence increased compared to 2004 to 2008, from 10.8 per 100,000 to 11.7 per 
100,000. Between 2008-2012, approximately 38,793 HPV-associated cancers were diagnosed 
annually in the United States, with approximately 79% of those cases being attributed to HPV. 
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Of those cases attributed to HPV, 93% are due to the HPV strains that are preventable with the 
Gardasil 9® vaccine.3  
Universal vaccination with Gardasil 9® has the potential to decrease the incidence of 
HPV-associated cancers by over two-thirds. Cervical cancer can theoretically be eradicated with 
universal vaccination, which would also reduce the need for additional medical care and invasive 
procedures that result from an abnormal cervical screening. Non-cervical HPV-associated 
cancers, including oropharyngeal, penile, anal, and rectal cancers, do not have established 
screening programs and the rates of these cancers will also dramatically decrease as a result of 
the Gardasil® vaccination.5   
While this vaccine holds great promise for decreasing the incidence of many cancers, 
vaccination rates have remained low. In 2014, national HPV vaccine coverage was 60% for 
adolescent girls and 42% for adolescent boys, leaving the unvaccinated adolescents at risk for 
contracting an HPV infection that may otherwise be preventable.6  
 
Methods 
Optional anonymous surveys (see Appendix A) were given to patients at the Health 
Services Pharmacy. If a patient chose to participate, they completed the survey and returned it to 
a collection box and were offered additional Gardasil® educational materials (see appendix B). 
The survey was offered to patients at the pharmacy from August 31 through November 24, 2016. 
After the survey period, surveys were analyzed to compare vaccination rates, knowledge of 
HPV, and opinion of the importance of vaccination.  
 
Results 
Eighty-six surveys were completed and submitted. Of the submitted surveys, 19 (22%) 
respondents were male and 67 (78%) were female. The most common age range of respondents 
was 18-22 years old (n=71, 83%), followed by ages 23-26 (n=11, 13%), and ages over 26 (n=4, 
5%). Thirty-two respondents (37%) reported that they had received the Gardasil® vaccine, 26 
respondents (30%) had not received the vaccine, and 28 respondents (33%) did not know if they 
had received the vaccine. Eleven percent of males reported that they had received the vaccine, 
and 45% of females reported vaccination. 
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If you have not received the vaccine, what are your reasons for not getting it? 
The most common reason for not receiving the vaccine was that respondents were not 
aware of the vaccine. Thirty-eight of respondents did not answer this question, the majority of 
whom reported that they had received the vaccine.   
 
Table 1: Reasons for non-vaccination 
Reason Frequency (n) 
Time 12% (8) 
Cost 3% (2) 
Against vaccines 3% (2) 
Unaware of the vaccine 31% (27) 
Safety concerns 6% (4) 
Other 7% (5) 
Did not answer question 44% (38) 
 
If the cost of the Gardasil® vaccine prevents you from getting it, would you get it if it were 
free? 
Forty-one respondents (48%) answered that they would get the vaccine if it were 
provided for free, 2 respondents (2%) would not get the vaccine if it were free, and 31 
respondents (36%) answered ‘not applicable’, most likely because they had already received the 
vaccine.  
 
Did you know that the Gardasil® vaccine is available at the Health Services Pharmacy on 
campus? 
Twenty-one respondents (24%) knew that Gardasil® is available at the Health Services 
Pharmacy while 60 respondents (70%) did not know of the vaccine’s availability. Five 
respondents (6%) did not answer this question.  
 
To the best of your knowledge, the Gardasil® vaccine is used to protect people from what 
pathogen? 
Most respondents selected the correct answer, human papilloma virus. The second most 
common answer was pertussis. Of the respondents who received the vaccine, 31 (96%) selected 
the correct answer, while only 17 (65%) of respondents who were unvaccinated answered this 
question correctly. 
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Table 2: Pathogen Gardasil® protects against 
Pathogen Frequency (n) 
Pertussis 7% (6) 
Measles 3% (3) 
Human Papilloma Virus 76% (65) 
Typhoid 2% (2) 
Multiple answers chosen 1% (1) 
No response 10% (9) 
 
To the best of your knowledge, what condition can Gardasil® help prevent people from 
acquiring? 
The correct answer, cervical cancer, was selected by most respondents. The second most 
common answer was hepatitis. Of the respondents who received the vaccine, 26 (81%) answered 
this question correctly, while only 9 (35%) respondents who were unvaccinated were correct. 
 
Table 3: Condition Gardasil® protects against  
Condition Frequency (n) 
Influenza 7% (6) 
Cervical Cancer 51% (44) 
Hepatitis 20% (17) 
Meningitis 6% (5) 
Multiple answers chosen 7% (6) 
No response 9% (8) 
 
In your opinion, how important is getting the Gardasil® vaccine? 
While 40% of respondents thought that receiving the Gardasil® vaccine was ‘very 
important’, 29% had no opinion on the value of Gardasil®. More respondents who had received 
the vaccine believed the vaccine to be ‘very important’ compared to those who had not received 
the vaccine (23 [71%] versus 3 [11%], respectively).  
 
Table 4: Importance of Gardasil®  
Opinion Frequency (n) 
No opinion 29% (25) 
Not important 1% (1) 
Somewhat important 23% (20) 
Very important 40% (34) 
No response 7% (6) 
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Discussion 
If vaccination data obtained from this study is correct and extrapolated to the UM student 
population, vaccination rates of UM students are much lower than the national averages for both 
men and women. This data also highlights a stark contrast in vaccination rates between men and 
women at UM. A possible explanation for this occurrence is that Gardasil® was initially 
recommended exclusively for females; it was not until 2016 that the American Cancer Society 
updated its recommendations on HPV vaccination to include males.7  
Lack of knowledge of HPV may be influencing low vaccination rates in this population, 
which is supported by responses to the knowledge-based survey questions. More respondents 
who were vaccinated answered the knowledge questions correctly compared to unvaccinated 
respondents. This data shows that people who have received the vaccine may be more likely to 
have knowledge of HPV and its associated cancers. Additionally, most respondents did not know 
that Gardasil® is available on campus. These results support the implementation of a Gardasil® 
education campaign on campus to increase awareness about HPV and vaccination. This would 
likely increase vaccination rates and support of Gardasil® among the student population.  
Possible limitations to these results include sample size, recall bias, and selection bias. 
With over 13,000 undergraduate students enrolled at UM, 86 is a very small sample size and may 
not give a true reflection of this population. Respondents may also not remember if they received 
the vaccine if they were vaccinated as an adolescent. In addition, students utilizing the Health 
Service Pharmacy may be more likely to be vaccinated due to their interest in accessing 
healthcare.   
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APPENDIX A 
Gardasil® Survey 
 
 
 
 
 
 
 
 
 
 
 
Student Gardasil® Survey 2016 
What is your gender? □ Male □ Female □ Prefer not to answer 
What is your age range? □ 18-22 □ 23-26 □ > 26 
Have you received the Gardasil® vaccine? □ Yes □ No □ Don’t know 
If you have not received the vaccine, what are 
your reasons for not getting it? 
(mark all that apply) 
□ Time □ Cost of the   
…vaccine 
□ Don’t believe in 
…vaccines 
□ Unaware of 
…this vaccine 
□ Safety concerns 
 
Other_______________ 
 
If the cost of the Gardasil® vaccine prevents you 
from getting it, would you get it if it were free? 
□ Yes □ No □ Not applicable 
Did you know that the Gardasil® vaccine is 
available at the Health Service Pharmacy on 
campus? 
□ Yes □ No 
To the best of your knowledge, the Gardasil® 
vaccine is used to protect people from what 
pathogen? 
□ Pertussis □ Measles □ Human 
…Papilloma-
…virus 
□ Typhoid 
To the best of your knowledge, what condition can 
Gardasil® help prevent people from acquiring? 
□ Influenza □ Cervical 
…cancer 
□ Hepatitis □ Meningitis 
In your opinion, how important is getting the 
Gardasil® vaccine? 
□ No opinion □ Not 
…important 
□ Somewhat 
…important 
□ Very 
…important 
 
The purpose of this anonymous survey is to assess student knowledge and values pertaining to the Gardasil® vaccine. 
Please place completed surveys in the drop box at the pharmacy 
If you have any questions regarding the Gardasil® vaccine, please consult the pharmacist. 
Thank you for participating in the survey! 
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APPENDIX B 
Gardasil® information provided to respondents 
 
